ReviewTherapeutic advances in hematology2021

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor.

Alexander K Glaros et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.